Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 科学研究和技术服务业
Company Introduction 和元生物技术（上海）股份有限公司（股票代码：688238）成立于2013年，是一家聚焦基因治疗领域的生物科技公司，专注于为基因治疗的基础研究提供基因治疗载体研制、基因功能研究、药物靶点及药效研究等CRO服务，为基因药物的研发提供工艺开发及测试、IND-CMC药学研究、临床样品GMP生产等CDMO服务。 公司以“赋能基因治疗，共守生命健康”为使命，围绕病毒载体研发和大规模生产工艺开发，打造了基因治疗载体开发技术；基因治疗载体生产工艺及质控技术两大核心技术集群，建立了适用于多种基因药物的大规模、高灵活性GMP生产体系，向基因治疗领域提供：①质粒、腺相关病毒、慢病毒等载体产品；②溶瘤疱疹病毒、溶瘤痘病毒等多种溶瘤病毒产品；③CAR-T、CAR-NK等细胞治疗产品；④mRNA等其他产品的技术研究、工艺开发和GMP生产服务。 基于公司自主搭建的分子生物学平台、实验级病毒载体包装平台、细胞功能研究平台、SPF级动物实验平台、临床级基因治疗载体和细胞治疗工艺开发平台、质控技术研究平台等全面的技术平台，依托公司已有的近5000平米研发中心、超10000平方米基因治疗载体GMP生产中心，以及在上海自由贸易试验区临港新片区的77,000平方米精准医疗产业基地，公司将坚持以客户为中心、以提供专业服务为己任，打造国际领先的基因和细胞治疗CXO集团企业，加快基因治疗的基础研究、药物发现、药学研究、临床和商业化进程，推动基因治疗行业发展，造福人类健康！
Main Business 为基因治疗的基础研究提供基因治疗载体研制、基因功能研究等CRO服务，以及为基因药物的研发提供IND-CMC药学研究、临床样品GMP生产等CDMO服务
Legal Representative 潘讴东
Top Executives
董事长：潘讴东
董事：由庆睿,潘俊屹,袁可嘉,潘讴东,王富杰,殷珊
独立董事：宋正奇,甘丽凝,GANG WANG（王刚）
Top 5 Shareholder
Shareholder name Nature Holding Date
潘讴东限售股18.97%30/09/2024
上海檀英投资合伙企业(有限合伙）流通A股4.75%30/09/2024
上海张江科技创业投资有限公司流通A股3.58%30/09/2024
浙江华睿盛银创业投资有限公司流通A股3.04%30/09/2024
上海正心谷投资管理有限公司－上海乐永投资合伙企业（有限合伙）流通A股2.20%30/09/2024
Company Secretary 徐鲁媛
Solicitors 上海市金茂律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 021-58180909
Fax No 021-55230588
Website www.obiosh.com
Email zhengquanbu@obiosh.com
Company Address
Register: 上海市浦东新区国际医学园区紫萍路908弄19号楼
Office: 上海市浦东新区国际医学园区紫萍路908弄19号楼
Listing Date 22/03/2022
Shares Capital
Shares Capital: 647,433,100
Total A Share: 647,433,100
Listed A Share: 466,743,108
Non-tradable A Share: 180,689,992
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -0.199
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 3.179
Market Capitalization(RMB) 2.558B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.